Compare Lamb Weston Holdings Inc (LW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Lamb Weston Holdings Inc trades at $52.79 (market cap $7.23B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.6× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 2.89% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| LW | VRTX | |
|---|---|---|
Market Cap | $7.23B | $134.25B |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $529.65 |
52-Week Low | $38.48 | $376.62 |
Enterprise Value | $11.10B | $128.37B |
Dividend Yield | 2.89% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
